Phage-Based Vaccine Platforms for Typhoid Fever: A Transformative Approach to Global Health and Antimicrobial Resistance.
4 affiliations
- 1Department of Microbiology, Faculty of Natural and Applied Sciences, Plateau State University, Bokkos 932112, Plateau State, Nigeria.
- 2Center for Phage Biology and Therapeutics (CENPBAT) LTD/GTE, Jos 930105, Plateau State, Nigeria.
- 3School of Pharmacy, University of Waterloo, 10A Victoria St S, Kitchener, ON N2G 1C5, Canada.
- 4Theraphage, 151 Charles St W Suite # 199, Kitchener, ON N2G 1H6, Canada.
Abstract
Typhoid fever, caused by Salmonella enterica serovars Typhi and Paratyphi, remains a major public health threat across Africa and Asia and causes substantial annual morbidity. Transmission persists in low- and middle-income countries (LMICs), where access to safe water and sanitation is limited. While improvements in water, sanitation, and hygiene (WASH) are essential, slow implementation makes vaccination the most practical preventive strategy. Current licensed vaccines have limitations, including suboptimal immune coverage in infants, limited duration of protection, and cold-chain requirements. This review examines bacteriophage-based vaccine platforms as emerging preclinical strategies for typhoid prevention. Phage technologies, including phage display, phage DNA, and hybrid models, offer potential advantages such as multivalent antigen display, projected thermostability, and cost-efficient production using bacterial manufacturing systems. Based on animal immunogenicity and proof-of-concept studies, these systems could theoretically induce durable immunity and broaden age-group protection, although their clinical feasibility and scalability remain unproven. We evaluate key technical hurdles, including endotoxin contamination, host-strain engineering, and payload-expression constraints. We also discuss how these potentially low-cost platforms may contribute to global antimicrobial resistance (AMR) mitigation efforts. Although phage-based vaccines remain in the preclinical stage, they represent promising research platforms for advancing vaccine equity and infectious disease resilience, provided regulatory and technical challenges are overcome. However, significant translational gaps must still be bridged before clinical application can be realized.
Related
- A phytochemical–nanotechnology platform exhibits complementary antimicrobial and immunomodulatory effects in experimental fowl typhoid
- Evaluating the impact and cost-effectiveness of typhoid conjugate vaccine schedules across diverse settings: A multi-model comparison
- Exploring tumor-derived exosomes as promising antigenic platforms: novel vaccine and immunotherapy strategies for “cold” colorectal cancer
- Antimicrobial Resistance (AMR) Surveillance: Ten Years On.
- Editorial: Evolution of antimicrobial resistance in intracellular bacterial pathogens: a genomic and historical perspective
BibTeX
@article{tipah2026phagebased,
title = {{Phage-Based Vaccine Platforms for Typhoid Fever: A Transformative Approach to Global Health and Antimicrobial Resistance.}},
author = {Tambe David Tipah and Nnaemeka Emmanuel Nnadi and Roderick A Slavcev},
journal = {Vaccines},
year = {2026},
month = oct,
doi = {10.3390/vaccines14100869},
url = {https://europepmc.org/article/MED/42931398},
note = {CC BY},
}
RIS
TY - JOUR
TI - Phage-Based Vaccine Platforms for Typhoid Fever: A Transformative Approach to Global Health and Antimicrobial Resistance.
AU - Tambe David Tipah
AU - Nnaemeka Emmanuel Nnadi
AU - Roderick A Slavcev
PY - 2026
DA - 2026/10/01
JO - Vaccines
DO - 10.3390/vaccines14100869
UR - https://europepmc.org/article/MED/42931398
AB - Typhoid fever, caused by Salmonella enterica serovars Typhi and Paratyphi, remains a major public health threat across Africa and Asia and causes substantial annual morbidity. Transmission persists in low- and middle-income countries (LMICs), where access to safe water and sanitation is limited. While improvements in water, sanitation, and hygiene (WASH) are essential, slow implementation makes vaccination the most practical preventive strategy. Current licensed vaccines have limitations, including suboptimal immune coverage in infants, limited duration of protection, and cold-chain requirements. This review examines bacteriophage-based vaccine platforms as emerging preclinical strategies for typhoid prevention. Phage technologies, including phage display, phage DNA, and hybrid models, offer potential advantages such as multivalent antigen display, projected thermostability, and cost-efficient production using bacterial manufacturing systems. Based on animal immunogenicity and proof-of-concept studies, these systems could theoretically induce durable immunity and broaden age-group protection, although their clinical feasibility and scalability remain unproven. We evaluate key technical hurdles, including endotoxin contamination, host-strain engineering, and payload-expression constraints. We also discuss how these potentially low-cost platforms may contribute to global antimicrobial resistance (AMR) mitigation efforts. Although phage-based vaccines remain in the preclinical stage, they represent promising research platforms for advancing vaccine equity and infectious disease resilience, provided regulatory and technical challenges are overcome. However, significant translational gaps must still be bridged before clinical application can be realized.
SN - 2076-393X
ER -